- November 7, 2018
Event LocationWhite Oak Campus: The Great Room
10903 New Hampshire Ave
Building 31, Room 1503
Silver Spring, MD 20993
The meeting of the Allergenic Products Advisory Committee scheduled for November 7, 2018, is canceled. This meeting was announced in the Federal Register of Wednesday, September 26, 2018 (Vol. 83, No. 187, FR pages 48634, 48635).
The November 7, 2018 Allergenic Products Advisory Committee meeting, to discuss the use of challenge studies in the clinical development of allergenic products for the diagnosis and treatment of allergy due to aeroallergens, has been canceled to allow time for the FDA to review and resolve issues. The agency intends to schedule an Advisory Committee meeting in the future, as needed.
CONTACT: CAPT Serina A. Hunter-Thomas, Center for Biologics Evaluation and Research, Food and Drug Administration, 10903, New Hampshire Ave., Bldg. 71, Rm. 6338, Silver Spring, MD, 20993, at 240-402-5771, email@example.com, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area).
A notice in the Federal Register about last minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice. Therefore, you should always check the agency’s website or call the committee’s Designated Federal Officer (see Contact Information) to learn about possible modifications before coming to the meeting.
Persons attending FDA’s advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets. FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with disabilities. If you require accommodations due to a disability, please contact the committee’s Designated Federal Officer (see Contact Information) at least 7 days in advance of the meeting.
Answers to commonly asked questions including information regarding special accommodations due to a disability may be accessed at: Common Questions and Answers about FDA Advisory Committee Meetings.
FDA is committed to the orderly conduct of its advisory committee meetings. Please visit our Web site at Public Conduct During FDA Advisory Committee Meetings for procedures on public conduct during advisory committee meetings.
Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app.2).